German authors last year described the first 2 cases of patients with psoriasis in whom treatment with, among other things, anti-IL-17A antibodies failed, but who responded to the blockade of interleukins IL-17A/IL-17F with bimekizumab after its approval by the European Medicines Agency (EMA).
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
